Haemacure and Baxter reach settlement:
This article was originally published in Clinica
Canadian biomaterial company Haemacure has reached a C$2.3 million ($1.5 million) settlement with Baxter International, the supplier of Hemaseel APR fibrin sealant, payable to Haemacure. The settlement amount was credited against the licence fee of C$3.8 million payable to Baxter. The dispute concerned the cost of the product and other financial issues in the companies' manufacturing agreement. The cost review was carried out by a trustee appointed by the US Federal Trade Commission at Haemacure's request. The two companies have also agreed fixed prices for the remainder of the manufacturing agreement.